ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CABG Cabg Medical (MM)

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type
Cabg Medical (MM) NASDAQ:CABG NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0 -

CABG Medical Schedules Operating Results Conference Call for November 2, 2005

24/10/2005 10:00pm

PR Newswire (US)


Cabg Medical (NASDAQ:CABG)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Cabg Medical Charts.
MINNEAPOLIS, Oct. 24 /PRNewswire-FirstCall/ -- CABG Medical, Inc. (NASDAQ:CABG) today announced that it will report its financial results for the third quarter 2005 after the market close on November 2, 2005. The Company will hold a conference call the same day at 4:30 p.m. Eastern Standard Time (3:30 p.m., Central Standard Time). The call will be hosted by Manny Villafana, Chairman and Chief Executive Officer, and John Babitt, President and Chief Financial Officer. (Logo: http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO ) The teleconference can be accessed via the "Investor Relations Section" of the Company's website at http://www.cabgmedical.com/investorRelations.html or by calling 1-800-475-3716. Please dial in or access the website 10 to 15 minutes prior to the beginning of the call. A replay of the conference call will be available 24 hours after the conference call concludes on the Company's website http://www.cabgmedical.com/investorRelations.html and will be available until November 30, 2005. About CABG Medical CABG Medical, Inc. is a medical technology company developing technologies and therapies to improve the treatment of coronary heart disease by advancing conventional bypass surgery. We have designed our first product, the Holly Graft(TM) System, by leveraging our understanding of flow dynamics, material sciences and drug combinations to create a drug-eluting graft (DEG) for coronary artery bypass surgery. Safe Harbor This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including regulatory actions, competition, and management of growth. For a discussion of these and other risks and uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission. http://www.newscom.com/cgi-bin/prnh/20050114/CGF013LOGO http://photoarchive.ap.org/ DATASOURCE: CABG Medical, Inc. CONTACT: Manny Villafana, Chairman & CEO, or John L. Babitt, President & CFO, both of CABG Medical, Inc., +1-763-258-8005, or fax, +1-763-258-8008 Web site: http://www.cabgmedical.com/ http://www.cabgmedical.com/investorRelations.html

Copyright

1 Year Cabg Medical Chart

1 Year Cabg Medical Chart

1 Month Cabg Medical Chart

1 Month Cabg Medical Chart

Your Recent History

Delayed Upgrade Clock